Report cover image

APAC Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2031

Publisher Data Bridge Market Research
Published Oct 01, 2023
Length 191 Pages
SKU # DAABD18360489

Description

APAC Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2031


The Asia-Pacific duchenne muscular dystrophy treatment market is expected to reach USD 1,215,876.64 thousand by 2030 from USD 331,133.48 thousand in 2022, growing at a CAGR of 18.2% in the forecast period of 2023 to 2030.
Market Segmentation
Asia-Pacific Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and Rest of Asia-Pacific) - Industry Trends and Forecast to 2030

Overview of Asia-Pacific Duchenne Muscular Dystrophy Treatment Market Dynamics

Driver
• Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease

Restraint

• High treatment cost of DMD disorder

Opportunity

• Strategic initiatives by key market players

Market Players

Some of the key market players for Asia-Pacific duchenne muscular dystrophy treatment market are:

• Sarepta Therapeutics, Inc.
• Solid Biosciences Inc.
• Capricor Therapeutics, Inc.
• Dyne Therapeutics
• BioMarin
• Stealth BioTherapeutics Inc
• Avidity Biosciences
• ReveraGen
• BioPharma, Inc.
• TAIHO PHARMACEUTICAL CO., LTD.
• Akashi RX
• ITALFARMACO S.p.
• NS Pharma, Inc.
• PTC Therapeutics.
• Pfizer Inc.
• FibroGen, Inc.
• SANTHERA PHARMACEUTICALS
• F. Hoffmann-La Roche Ltd

Table of Contents

191 Pages
1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of The Asia-pacific Duchenne Muscular Dystrophy Treatment Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Multivariate Modelling
2.7 Treatment Type Segment Lifeline Curve
2.8 Market End User Coverage Grid
2.9 Dbmr Market Position Grid
2.10 Vendor Share Analysis
2.11 Secondary Sources
2.12 Assumptions
3 Executive Summary
4 Premium Insights
4.1 Pestel's Model
4.2 Porter's Five Forces Model
4.3 Pricing Analysis
5 Asia-pacific Duchenne Muscular Dystrophy Treatment Market: Regulations
5.1 Regulations In U.S.
5.2 Regulattions In Europe
5.3 Regulattions In Australia
5.4 Regulations In South Africa
5.5 Regulations In Brazil 47 
6 Market Overview
6.1 Drivers
6.1.1 Increasing Prevalence And Impact Of Duchenne Muscular Dystrophy (Dmd) Disease
6.1.2 Introduction Of Novel Therapies For Dmd Disorder
6.1.3 Rising Awareness For Dmd Treatments
6.1.4 Increase In The Number Of Clinical Trials Is A Recent Trend
6.2 Restraints
6.2.1 Limited Availability Of Dmd Treatments Due To Lack Of Advance Technology
6.2.2 High Treatment Cost Of Dmd Disorder
6.3 Opportunities
6.3.1 Development Of Healthcare Infrastructure And Increasing Investment
6.3.2 Rising Patient Inclination Towards Personalized And Effective Therapies
6.3.3 Strategic Initiatives By The Key Market Players
6.3.4 Support From Patient Advocacy Groups On The Regulatory Approval Process
6.4 Challenges
6.4.1 Lack Of Standardization In Dmd Diagnosis
6.4.2 Ethical Considerations Related To Permanent Alteration Of A Patient's Genetic Code
7 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Treatment Type
7.1 Overview
7.2 Molecular-based Therapies
7.2.1 Antisense Oligonucleotide Therapy
7.2.1.1 Exondys 51
7.2.1.2 Amondys 45
7.2.1.3 Vyondys 53
7.3 Nonsense Mutation
7.3.1.1 Translarna
7.4 Steroid Therapy
7.4.1 Prednisone
7.4.2 Deflazacort
7.5 Others 67 
8 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Therapy
8.1 Overview
8.2 Exon Skipping Approach
8.2.1 Multi-exon Skipping Approach
8.2.2 Single-exon Skipping Approach
8.3 Mutation Suppression
8.4 Dystrophin-targeted Therapies
8.4.1 Gene Therapies
8.4.2 Cell Therapies
8.4.2.1 Gene Editing
8.4.2.2 Gene Addition
9 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration
9.1 Overview
9.2 Parenteral
9.3 Oral
9.4 Others
10 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By End User
10.1 Overview
10.2 Hospitals
10.3 Specialty Clinics
10.4 Homecare
10.5 Others
11 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel
11.1 Overview
11.2 Hospital Pharmacy
11.3 Retail Pharmacy
11.4 Online Pharmacy 97 
12 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Region
12.1 Asia-pacific
12.1.1 China
12.1.2 Japan
12.1.3 India
12.1.4 South Korea
12.1.5 Australia
12.1.6 Singapore
12.1.7 Thailand
12.1.8 Malaysia
12.1.9 Indonesia
12.1.10 Philippines
12.1.11 Rest Of Asia-pacific
13 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, Company Landscape
13.1 Company Share Analysis: Asia Pacific
14 Swot Analysis
15 Company Profiles
15.1 Sarepta Therapeutics, Inc.
15.1.1 Company Snapshot
15.1.1 Revenue Analysis
15.1.2 Company Share Analysis
15.1.3 Product Portfolio
15.1.4 Pipeline Portfolio
15.1.5 Recent Developments
15.2 F. Hoffmann-la Roche Ltd
15.2.1 Company Snapshot
15.2.2 Revenue Analysis
15.2.3 Company Share Analysis
15.2.4 Product Portfolio
15.2.5 Pipeline Portfolio
15.2.6 Recent Developments
15.3 Ptc Therapeutics.
15.3.1 Company Snapshot
15.3.2 Revenue Analysis
15.3.3 Company Share Analysis
15.3.4 Product Portfolio
15.3.5 Recent Development
15.4 Pfizer Inc.
15.4.1 Company Snapshot
15.4.2 Revenue Analysis
15.4.3 Company Share Analysis
15.4.4 Pipeline Portfolio
15.4.5 Product Portfolio
15.4.6 Recent Development
15.5 Akashi Rx
15.5.1 Company Snapshot
15.5.2 Pipeline Portfolio
15.5.3 Recent Developments
15.6 Avidity Biosciences
15.6.1 Company Snapshot
15.6.2 Revenue Analysis
15.6.3 Pipeline Portfolio
15.6.4 Recent Developments
15.7 Biomarin
15.7.1 Company Snapshot
15.7.2 Revenue Analysis
15.7.3 Pipeline Portfolio
15.7.4 Recent Developments
15.8 Capricor Therapeutics, Inc.
15.8.1 Company Snapshot
15.8.2 Pipeline Portfolio
15.8.3 Recent Developments
15.9 Dyne Therapeutics
15.9.1 Company Snapshot
15.9.2 Pipeline Portfolio
15.9.3 Recent Developments
15.10 Fibrogen, Inc.
15.10.1 Company Snapshot
15.10.2 Revenue Analysis
15.10.3 Pipeline Portfolio
15.10.4 Recent Development
15.11 Italfarmaco S.P.A.
15.11.1 Company Snapshot
15.11.2 Pipeline Portfolio
15.11.3 Recent Development
15.12 Ns Pharma, Inc.
15.12.1 Company Snapshot
15.12.2 Pipeline Portfolio
15.12.3 Recent Developments
15.13 Reveragen Biopharma, Inc.
15.13.1 Company Snapshot
15.13.2 Pipeline Portfolio
15.13.3 Recent Development
15.14 Santhera Pharmaceuticals
15.14.1 Company Snapshot
15.14.2 Revenue Analysis
15.14.3 Pipeline Portfolio
15.14.4 Recent Development
15.15 Taiho Pharmaceutical Co., Ltd.
15.15.1 Company Snapshot
15.15.2 Pipeline Portfolio
15.15.3 Recent Developments
15.16 Solid Biosciences Inc.
15.16.1 Company Snapshot
15.16.2 Pipeline Portfolio
15.16.3 Recent Development
15.17 Stealth Biotherapeutics Inc
15.17.1 Company Snapshot
15.17.2 Pipeline Portfolio
15.17.3 Recent Development
16 Questionnaire
17 Related Reports
List Of Tables
Table 1 List Of Prices For Approved Drugs Of The Asia-pacific Duchenne Muscular Dystrophy Treatment Market
Table 2 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Treatment Type , 2021-2030 (Usd Thousand)
Table 3 Asia-pacific Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 4 Asia-pacific Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 5 Asia-pacific Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 6 Asia-pacific Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 7 Asia-pacific Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 8 Asia-pacific Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 9 Asia-pacific Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 10 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 11 Asia-pacific Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 12 Asia-pacific Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 13 Asia-pacific Mutation Suppression In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 14 Asia-pacific Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 15 Asia-pacific Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 16 Asia-pacific Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 17 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration , 2021-2030 (Usd Thousand)
Table 18 Asia-pacific Parenteral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 19 Asia-pacific Oral In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 20 Asia-pacific Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 21 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By End Users, 2021-2030 (Usd Thousand)
Table 22 Asia-pacific Hospitals In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 23 Asia-pacific Speciality Clinics In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 24 Asia-pacific Homecare In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 25 Asia-pacific Others In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 26 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 27 Asia-pacific Hospital Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 28 Asia-pacific Retail Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 29 Asia-pacific Online Pharmacy In Duchenne Muscular Dystrophy Treatment Market, By Region, 2021-2030 (Usd Thousand)
Table 30 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Country, 2021-2030 (Usd Thousand)
Table 31 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 32 Asia-pacific Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 33 Asia-pacific Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 34 Asia-pacific Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 35 Asia-pacific Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 36 Asia-pacific Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 37 Asia-pacific Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 38 Asia-pacific Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 39 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 40 Asia-pacific Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 41 Asia-pacific Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 42 Asia-pacific Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 43 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 44 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 45 Asia-pacific Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 46 China Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 47 China Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 48 China Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 49 China Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 50 China Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 51 China Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 52 China Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 53 China Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 54 China Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 55 China Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 56 China Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 57 China Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 58 China Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 59 China Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 60 China Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 61 China Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 62 China Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 63 China Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 64 Japan Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 65 Japan Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 66 Japan Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 67 Japan Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 68 Japan Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 69 Japan Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 70 Japan Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 71 Japan Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 72 Japan Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 73 Japan Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 74 Japan Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 75 Japan Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 76 Japan Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 77 Japan Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 78 Japan Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 79 Japan Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 80 Japan Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 81 Japan Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 82 India Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 83 India Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 84 India Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 85 India Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 86 India Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 87 India Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 88 India Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 89 India Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 90 India Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 91 India Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 92 India Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 93 India Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 94 India Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 95 India Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 96 India Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 97 India Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 98 India Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 99 South Korea Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 100 South Korea Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 101 South Korea Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 102 South Korea Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 103 South Korea Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 104 South Korea Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 105 South Korea Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 106 South Korea Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 107 South Korea Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 108 South Korea Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 109 South Korea Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 110 South Koreaduchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 111 South Korea Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 112 South Korea Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 113 South Korea Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 114 South Korea Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 115 South Korea Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 116 South Korea Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 117 Australia Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 118 Australia Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 119 Australia Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 120 Australia Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 121 Australia Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 122 Australia Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 123 Australia Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 124 Australia Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 125 Australia Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 126 Australia Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 127 Australia Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 128 Australia Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 129 Australia Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 130 Australia Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 131 Australia Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 132 Australia Duchenne Muscular Dystrophy Treatment Market, By Route Of Administration, 2021-2030 (Usd Thousand)
Table 133 Australia Duchenne Muscular Dystrophy Treatment Market, By End User, 2021-2030 (Usd Thousand)
Table 134 Australia Duchenne Muscular Dystrophy Treatment Market, By Distribution Channel, 2021-2030 (Usd Thousand)
Table 135 Singapore Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 136 Singapore Molecular-based Therapies In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 137 Singapore Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 138 Singapore Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 139 Singapore Antisense Oligonucleotide Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 140 Singapore Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 141 Singapore Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 142 Singapore Nonsense Mutation In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 143 Singapore Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Usd Thousand)
Table 144 Singapore Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Volume)
Table 145 Singapore Steroid Therapy In Duchenne Muscular Dystrophy Treatment Market, By Treatment Type, 2021-2030 (Asp)
Table 146 Singapore Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 147 Singapore Exon Skipping Approach In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 148 Singapore Dystrophin-targeted Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)
Table 149 Singapore Cell Therapies In Duchenne Muscular Dystrophy Treatment Market, By Therapy, 2021-2030 (Usd Thousand)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us